Heterocyclic compounds for the treatment of neurological and psychological disorders
申请人:Alkermes Pharma Ireland Limited
公开号:US11518745B2
公开(公告)日:2022-12-06
Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
公开了式 I 的内酰胺化合物及其在治疗神经和精神疾病(包括精神分裂症、躁郁症、焦虑症和失眠症)方面的用途。